Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01202279 · ClinicalTrials.gov registry record · Phase 4

Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI

A Phase 4 study, sponsored by Reckitt Benckiser.

Completed
Registry status
Phase 4
Development phase
1,179
Enrollment target

NCT01202279: Completed Phase 4 study, sponsored by Reckitt Benckiser.

NCT01202279 is a Phase 4 study that has completed, run by Reckitt Benckiser. The registered enrollment target is 1,179 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (128% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01202279, a Phase 4 study, has completed, sponsored by Reckitt Benckiser.

COMPLETED
Registry status
Phase 4
Development phase
1,179 participants
Enrollment target

Study Summary

The purpose of this study is to determine if treatment with Mucinex D lowers the use of antibiotics in the treatment of upper respiratory infection when compared to placebo

Primary Outcome

Number of patients who received an antibiotic

Interventions

  • DEVICE Placebo
  • DRUG Guaifenesin

Trial Details

FieldValue
Enrollment Target 1,179 participants
Start Date 2009-10
Est. Completion 2010-07
Phase Phase 4
Reckitt Benckiser

8 total trials

What the finished NCT01202279 record still lists

NCT01202279 is an interventional study that assigns participants to a tested intervention. Its 1,179 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (128% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01202279 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01202279 about?

NCT01202279 is a clinical study titled "Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI". The purpose of this study is to determine if treatment with Mucinex D lowers the use of antibiotics in the treatment of upper respiratory infection when compared to placebo

What is the current status of trial NCT01202279?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,179 participants. The study started on 2009-10. Estimated completion is 2010-07.

What interventions are being tested in trial NCT01202279?

The interventions under investigation include: Placebo (DEVICE), Guaifenesin (DRUG).

Who is sponsoring clinical trial NCT01202279?

This trial is sponsored by Reckitt Benckiser, which has 8 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01202279's enrollment target sits among peer trials

1,179 63rd of 2000 higher than 1,938 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05688436 · 1,178 participants

    A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

  • NCT06931275 · 1,178 participants · NA

    Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes

  • NCT07286058 · 1,182 participants · Phase 3

    Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

  • NCT06133322 · 1,176 participants · NA

    Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01202279, the US trial registry maintained by the National Library of Medicine. NCT01202279 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.